Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK blood cancer drug nearly halves risk of death in late-stage trial
08:03am, Sunday, 02'nd Jun 2024
GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage s
Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 31'st May 2024
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK development pipeline underrated suggests Deutsche Bank
08:39am, Thursday, 30'th May 2024
GSK's development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma's top R&D executives. Work needs to be done to rebuild the inno
AstraZeneca started at buy at Goldman, which rates GSK a neutral
06:34am, Thursday, 30'th May 2024
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
GSK plc: Long-Term Cash Cow
03:05am, Tuesday, 28'th May 2024
On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 mi
GSK found not guilty in Zantac trial
02:34am, Friday, 24'th May 2024
British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois, US, over its heartburn medication Zantac. A jury determined that Zantac
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 23'rd May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
12:16pm, Wednesday, 22'nd May 2024
GSK's GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.
GSK Breathes New Life Into Asthma Treatment With Depemokimab
11:19am, Wednesday, 22'nd May 2024
GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reducti
GSK: Zantac settlement could reach $2bn, says investment bank
07:36am, Tuesday, 21'st May 2024
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the inv
GSK says late-stage trials of potential blockbuster asthma drug met their goals
03:10am, Tuesday, 21'st May 2024
GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.
GSK's asthma drug shows promise in reducing severe attacks
02:29am, Tuesday, 21'st May 2024
GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.
GSK faces whistleblower lawsuit over Zantac cancer risk
04:27pm, Monday, 20'th May 2024
GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn
GSK confirms exit of Haleon stake for £3.9 billion
03:18am, Friday, 17'th May 2024
GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant
GSK raises $1.5 bln from offloading Haleon stake at a discount
02:22am, Friday, 17'th May 2024
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
